Nieuws en video's - REGENERON PHARMACEUTICALS INC.

High School Seniors Win $1.8 Million at Regeneron Science Talent Search 2024 for Innovative Scientific Research on Artificial Intelligence, Cancer Metabolism and Mathematical Optimization PR Newswire TARRYTOWN, N.Y. and WASHINGTON, March 12, 2024 $250,000 top award goes to Achyuta Rajaram in the nation's oldest and most prestigious Science, Technology, Engineering and Math (STEM) competition for high school seniors TARRYTOWN, N.Y. and WASHINGTON , March 12, 2024 /PRNewswire/ -- Regeneron...

Top 40 High School Scientists in Prestigious Regeneron Science Talent Search to Compete for $1.8 Million in Awards PR Newswire TARRYTOWN, N.Y. and WASHINGTON, Jan. 24, 2024 Regeneron Science Talent Search Showcases Exceptional Young Leaders with Innovative Ideas in Science, Technology, Engineering and Math (STEM) TARRYTOWN, N.Y. and WASHINGTON , Jan. 24, 2024 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science (the Society) today announced the top 40 finalists...

Medison Pharma Announces Agreement with Regeneron Pharmaceuticals to Commercialize Libtayo® (cemiplimab) in Multiple Countries PR Newswire ZUG, Switzerland, Jan. 8, 2024 Libtayo (cemiplimab) is a leading PD-1 inhibitor that has shown efficacy in the treatment of certain patients with cutaneous squamous cell carcinoma, advanced basal cell carcinoma, advanced non-small cell lung cancer and advanced cervical cancer, and is approved by regulatory authorities in more than two dozen countries for...

Medison Pharma Announces Agreement with Regeneron Pharmaceuticals to Commercialize Libtayo® (cemiplimab) in Multiple Countries PR Newswire ZUG, Switzerland, Jan. 8, 2024 Libtayo (cemiplimab) is a leading PD-1 inhibitor that has shown efficacy in the treatment of certain patients with cutaneous squamous cell carcinoma, advanced basal cell carcinoma, advanced non-small cell lung cancer and advanced cervical cancer, and is approved by regulatory authorities in more than two dozen countries for...

Medison Pharma Announces Agreement with Regeneron Pharmaceuticals to Commercialize Libtayo® (cemiplimab) in Multiple Countries PR Newswire ZUG, Switzerland, Jan. 8, 2024 Libtayo (cemiplimab) is a leading PD-1 inhibitor that has shown efficacy in the treatment of certain patients with cutaneous squamous cell carcinoma, advanced basal cell carcinoma, advanced non-small cell lung cancer and advanced cervical cancer, and is approved by regulatory authorities in more than two dozen countries for...

Shareholder Alert: Ademi LLP investigates whether Decibel Therapeutics, Inc. has obtained a Fair Price in its transaction with Regeneron PR Newswire MILWAUKEE, Aug. 9, 2023 MILWAUKEE , Aug. 9, 2023 /PRNewswire/ -- Ademi LLP is investigating Decibel (NASDAQ: DBTX) for possible breaches of fiduciary duty and other violations of law in its transaction with Regeneron . Click here to learn how to join the action https://www.ademilaw.com/case/decibel-therapeutics-inc or call Guri Ademi toll-free at...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN PR Newswire NEW YORK, July 17, 2023 NEW YORK , July 17, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The investigation concerns whether Regeneron...

REGN ALERT: The Law Offices of Vincent Wong Investigate Regeneron Pharmaceuticals, Inc. for Potential Violations of Securities Laws PR Newswire NEW YORK, July 17, 2023 NEW YORK , July 17, 2023 /PRNewswire/ -- Attention Regeneron Pharmaceuticals, Inc. ("Regeneron") (NASDAQ: REGN) shareholders: The Law Offices of Vincent Wong announce that an investigation has commenced into Regeneron and certain of its officers and directors regarding potential securities fraud . The investigation concerns, in...

REGN FRAUD ALERT: Jakubowitz Law is Investigating Regeneron Pharmaceuticals, Inc. in Connection with Potential Violations of Federal Securities Laws PR Newswire NEW YORK, July 14, 2023 NEW YORK , July 14, 2023 /PRNewswire/ -- Jakubowitz Law announces that an investigation into potential securities fraud allegations has commenced on behalf of shareholders of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) To be contacted by a member of our team, fill out the form:...

REGN INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Regeneron Pharmaceuticals, Inc. PR Newswire NEW YORK, July 13, 2023 NEW YORK , July 13, 2023 /PRNewswire/ -- Levi & Korsinsky notifies investors that it has commenced an investigation of Regeneron Pharmaceuticals, Inc. ("Regeneron") (NASDAQ: REGN) concerning possible violations of federal securities laws. The investigation focuses on whether the Company...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN PR Newswire NEW YORK, July 12, 2023 NEW YORK , July 12, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The investigation concerns whether Regeneron...

INVESTIGATION ALERT: The Gross Law Firm Notifies Shareholders of Regeneron Pharmaceuticals, Inc. of an Investigation and Potential Class Action Lawsuit - (NASDAQ: REGN) PR Newswire NEW YORK, July 12, 2023 NEW YORK , July 12, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Regeneron Pharmaceuticals, Inc.: The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors....

REGN NEWS: The Klein Law Firm Initiates an Investigation Involving Possible Securities Fraud Violations by Officers of Regeneron Pharmaceuticals, Inc. PR Newswire NEW YORK, July 11, 2023 NEW YORK , July 11, 2023 /PRNewswire/ -- The Klein Law Firm announces that it is investigating allegations that Regeneron Pharmaceuticals, Inc. ("Regeneron") (NASDAQ: REGN) violated federal securities laws. CURRENT INVESTIGATION DETAILS: The investigation focuses on whether the Company issued false and/or...

REGN ALERT: The Law Offices of Vincent Wong Investigate Regeneron Pharmaceuticals, Inc. for Potential Violations of Securities Laws PR Newswire NEW YORK, July 10, 2023 NEW YORK , July 10, 2023 /PRNewswire/ -- Attention Regeneron Pharmaceuticals, Inc. ("Regeneron") (NASDAQ: REGN) shareholders: The Law Offices of Vincent Wong announce that an investigation has commenced into Regeneron and certain of its officers and directors regarding potential securities fraud . The investigation concerns, in...

REGN FRAUD ALERT: Jakubowitz Law is Investigating Regeneron Pharmaceuticals, Inc. in Connection with Potential Violations of Federal Securities Laws PR Newswire NEW YORK, July 7, 2023 NEW YORK , July 7, 2023 /PRNewswire/ -- Jakubowitz Law announces that an investigation into potential securities fraud allegations has commenced on behalf of shareholders of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) To be contacted by a member of our team, fill out the form:...

LOS ANGELES, CA / ACCESSWIRE / July 7, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Regeneron received a response letter from the FDA...

INVESTIGATION ALERT: The Gross Law Firm Notifies Shareholders of Regeneron Pharmaceuticals, Inc. of an Investigation and Potential Class Action Lawsuit - (NASDAQ: REGN) PR Newswire NEW YORK, July 6, 2023 NEW YORK , July 6, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Regeneron Pharmaceuticals, Inc.: The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors....

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. (“Regeneron” or “the Company”) (NASDAQ: REGN ) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Regeneron received a response letter from the FDA on June 27, 2023, declining to...

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. (“Regeneron” or “the Company”) (NASDAQ: REGN ) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Regeneron received a response letter from the FDA on June 27, 2023, declining to...

High School Scientists and Engineers Win Nearly $9 Million at the Regeneron International Science and Engineering Fair 2023 PR Newswire TARRYTOWN, N.Y. and WASHINGTON, May 19, 2023 $75,000 Top Award Goes to 17 -year-old Kaitlyn Wang for breakthrough innovation to accelerate exoplanet discovery in the largest international STEM competition for teens TARRYTOWN, N.Y. and WASHINGTON , May 19, 2023 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. and Society for Science (the Society) announced that...